The advantages seen in COVID-19 patients treated with SGLT2 inhibitors extend beyond glucose regulation and encompass impacts on heart muscle metabolism, adipokine activity, and vascular functions [35]. The gene discussed is SLC5A2; the disease is COVID-19.